Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis

Cited by (407)

Items 101–200 of 407

1. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial
   André Tadić, Daniel Wachtlin, Thomas Berger, Dieter F. Braus, Dietrich van Calker, Norbert Dahmen, Nadine Dreimüller, Alice Engel, Stanislav Gorbulev, Isabella Helmreich et al. · 2016 · European Neuropsychopharmacology
2. Bupropion pre-treatment of endotoxin-induced depressive symptoms
   Nicole DellaGioia, Lesley Devine, Brian P. Pittman, Jonas O. Hannestad · 2012 · Brain Behavior and Immunity
3. Meta-analysis: Fact or fiction? How to interpret meta-analyses
   Wolfgang Huf, Klaudius Kalcher, Gerald Pail, Michaela‐Elena Friedrich, Peter Filzmoser A, Siegfried F. Kasper · 2011 · The World Journal of Biological Psychiatry
4. Ensemble Learning for Early‐Response Prediction of Antidepressant Treatment in Major Depressive Disorder
   Cong Pei, Yurong Sun, Jinlong Zhu, Xinyi Wang, Yujie Zhang, Shuqiang Zhang, Zhijian Yao, Qing Lü · 2019 · Journal of Magnetic Resonance Imaging
5. Different functioning of prefrontal cortex predicts treatment response after a selective serotonin reuptake inhibitor treatment in patients with major depression
   Koji Masuda, Mari Nakanishi, Kana Okamoto, Chiwa Kawashima, Harumi Oshita, Ayako Inoue, Fuku Takita, Toshihiko Izumi, Yoshinobu Ishitobi, Haruka Higuma et al. · 2017 · Journal of Affective Disorders
6. Major depression: emerging therapeutics
   Srijan Sen, Gerard Sanacora · 2008 · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine
7. Guidelines for the diagnosis and treatment of depressive disorders in China: The second edition
   Yuan Feng, Le Xiao, Wei‐Wei Wang, Gabor Sandor Ungvari, Chee H. Ng, Gang Wang, Yu‐Tao Xiang · 2019 · Journal of Affective Disorders
8. Optimizing the management of depression: primary care experience
   Catherine Cameron, Jeffrey Habert, Leena Anand, Melissa Furtado · 2014 · Psychiatry Research
9. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression
   Zheng, Wei, Zhou, Yan-Ling, Liu, Wei-Jian, Wang, Cheng-Yu, Zhan, Yan-Ni, Lan, Xiao-Feng, Zhang, Bin, Ning, Yu-Ping · 2020 · Journal of Affective Disorders
10. Serotonin modulates asymmetric learning from reward and punishment in healthy human volunteers
    Michely, Jochen, Eldar, Eran, Erdman, Alon, Martin, Ingrid M., Dolan, Raymond J. · 2022 · Communications Biology
11. Fluoxetine Alleviates Behavioral Depression while Decreasing Acetylcholine Release in the Nucleus Accumbens Shell
    David T. Chau, Pedro V. Rada, Kay Kim, Rebecca A. Kosloff, Bartley G. Hoebel · 2011 · Neuropsychopharmacology
12. Onset of action of antidepressants
    Andre T. Tylee, Paul Walters · 2007 · BMJ
13. Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements.
    M. Katz, C. Bowden, A. Frazer · 2010 · Journal of Affective Disorders
14. A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine-adjunct, placebo-controlled, pilot clinical study
    Gang Chen, Ruyan Wu, Dandan Zhu, Haosen Wang, Weiwei Tao, Wenda Xue, Baomei Xia, Li Ren, Xin‐Fu Zhou, Youchun Xia et al. · 2015 · Neuropsychiatric Disease and Treatment
15. Presynaptic 5-HT1A is Related to 5-HTT Receptor Density in the Human Brain
    Subrata K. Bose, Mitul Ashok Mehta, Sudhakar Selvaraj, Oliver David Howes, Rainer Hinz, Eugenii A. Rabiner, Paul M. Grasby, Federico Turkheimer, Venkatesha Murthy · 2011 · Neuropsychopharmacology
16. The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study
    Gordon Barraclough Parker, Bianca Blanch, Amelia Paterson, Dušan Hadži-Pavlović, E. Sheppard, Vijaya L Manicavasagar, Howe Synnott, Rebecca Graham, Paul Friend, David Gilfillan et al. · 2012 · Acta Psychiatrica Scandinavica
17. Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation
    Mario Pinzi, Andrea M. Fagiolini, Despoina Koukouna, Giacomo Gualtieri, Maria Beatrice Rescalli, Caterina Pierini, Simone Pardossi, Benjamin Patrizio, Alessandro Cuomo · 2025 · Cells
18. Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response.
    Carlos M. Grilo, Marney A. White, Robin M. Masheb, Ralitza V. Gueorguieva · 2015 · Journal of Consulting and Clinical Psychology
19. Therapy-resistant depression
    Tom Bschor · 2009 · Expert Review of Neurotherapeutics
20. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial
    Shinichiro Nakajima, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Jinichi Hirano, Tatsuhiko Yagihashi, Hiroyoshi Takeuchi, Takayuki Abe, Haruo Kashima, Masaru Mimura · 2011 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
21. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
    Amir Garakani, Jose M. Martinez, Sue M. Marcus, James Crofton Weaver, Karl Rickels, Maurizio Fava M. D, Jack Hirschowitz · 2008 · International Clinical Psychopharmacology
22. Circadian rhythm biomarker from wearable device data is related to concurrent antidepressant treatment response
    Farzana Ali, Ramin V. Parsey, Shan Lin, Joseph E. Schwartz, Christine DeLorenzo · 2023 · npj Digital Medicine
23. Role of Central Serotonin in Impulsivity and Compulsivity: Comparative Studies in Experimental Animals and Humans
    Trevor William Robbins, Molly J. Crockett · 2010 · Handbook of behavioral neuroscience
24. Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: A pilot study
    Paulina S. Rojas, Rosemarie Fritsch M, Romina Rojas, Pablo Jara, Jenny Lucy Fiedler · 2011 · Psychiatry Research
25. Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response
    Roselinde H. Kaiser, Henry W. Chase, Mary Louise Phillips, Thilo Deckersbach, Ramin V. Parsey, Maurizio Fava M. D, Patrick J. McGrath, Myrna M. Weissman, María A. Oquendo, Melvin G. McInnis et al. · 2022 · Biological Psychiatry
26. Cognitive neuropsychological theory: Reconciliation of psychological and biological approaches for depression
    Beata R. Godlewska · 2018 · Pharmacology & Therapeutics
27. Fluoxetine Might Improve Survival of Patients With COVID-19 Pneumonia: A Retrospective Case-Control Study
    Zsófia Németh, Anna Szűcs, József Vitrai, Dóra Juhász, János Pál Németh, András Holló · 2021 · Ideggyógyászati Szemle
28. Psilocybin and Other Classic Psychedelics in Depression
    David Nutt, Joseph M. Peill, Brandon Weiss, Kate Godfrey, Robin Lester Carhart-Harris, David Erritzøe · 2023 · Current topics in behavioral neurosciences
29. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate
    Matthew John Taylor, Beata R. Godlewska, Ray Norbury, Sudhakar Selvaraj, Jamie Near, Philip J. Cowen · 2012 · The International Journal of Neuropsychopharmacology
30. Probabilistic Reinforcement Learning and Anhedonia
    Brian D. Kangas, Andre Der‐Avakian, Diego A. Pizzagalli · 2022 · Current topics in behavioral neurosciences
31. The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram
    Danilo Arnone, Toby Wise, Christopher P. R. Walker, Philip J. Cowen, Oliver David Howes, Sudhakar Selvaraj · 2018 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
32. [Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].
    D. Gourion · 2008 · L'Encephale
33. Clinical features and drug induced side effects in early versus late antidepressant responders
    Chiara Fabbri, Agnese Marsano, Martina Balestri, Diana De Ronchi, Alessandro Serretti · 2013 · Journal of Psychiatric Research
34. An algorithm for the pharmacological treatment of depression
    Jan Spijker, Willem A. Nolen · 2009 · Acta Psychiatrica Scandinavica
35. Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015
    Melvyn Weibin Zhang, Ying X. Hong, Syeda Fabeha Husain, Keith M. Harris, Roger Ho · 2017 · PLoS ONE
36. Predicting Treatment Response in Major Depressive Disorder: The Impact of Early Symptomatic Improvement
    Paul A. Kudlow, Danielle S Cha, Roger S. Mclntyre · 2012 · The Canadian Journal of Psychiatry
37. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR⁎D
    Chiara Fabbri, Antonio Drago, Alessandro Serretti · 2012 · European Neuropsychopharmacology
38. Fish oil and depression: The skinny on fats
    Mansoor D. Burhani, Mark M. Rasenick · 2017 · Journal of Integrative Neuroscience
39. A Randomized Placebo-Controlled Trial of Omega-3 and Sertraline in Depressed Patients With or at Risk for Coronary Heart Disease
    Robert M. Carney, Kenneth E. Freedland, Eugene H. Rubin, Michael W. Rich, Brian C. Steinmeyer, William Stephen Harris · 2019 · The Journal of Clinical Psychiatry
40. The effects of KaiXinSan on depression and its association with lipid profiles: A randomized, double-blinded, placebo-controlled trial
    Yuan Hu, Chao Chen, Yichen Wang, Wenshan Yang, Yuanbo Wang, Weiyu Zhu, Can Yan, Ping Liu · 2021 · Phytomedicine
41. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder
    Joel Raskin, Jimmy Y. Xu, Daniel K. Kajdasz · 2007 · International Psychogeriatrics
42. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder
    André Tadić, Stefanie Wagner, Stanislav Gorbulev, Norbert Dahmen, Christoph Hiemke, Dieter F. Braus, Klaus Lieb · 2011 · BMC Psychiatry
43. Early Prediction of Fluoxetine Response for Han Chinese Inpatients With Major Depressive Disorder
    Ching‐Hua Lin, Hsien‐Yuan Lane, Cheng‐Chung Chen, Suh‐Hang Hank Juo, Cheng‐Fang Yen · 2011 · Journal of Clinical Psychopharmacology
44. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder
    David A. Fishbain, Michael J. Detke, Joachim Wernicke, Amy S. Chappell, Daniel K. Kajdasz · 2008 · Current Medical Research and Opinion
45. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis
    IM Omori, Norio Watanabe, Atsuo Nakagawa, Tatsuo Akechi, Andrea Cipriani, Corrado Barbui, Hugh McGuire, Rachel C. Churchill, Toshi A. Furukawa · 2008 · Journal of Psychopharmacology
46. Escitalopram modulates learning content-specific neuroplasticity of functional brain networks
    Manfred Klöbl, René Seiger, Thomas Vanicek, Patricia Anna Handschuh, Murray Bruce Reed, Benjamin Spurny‐Dworak, Vera Ritter, Godber Mathis Godbersen, Gregor Gryglewski, Christoph Kraus et al. · 2021 · NeuroImage
47. Attention deficit-hyperactivity disorder and early-onset bipolar disorder: two facets of one entity?
    Florian Daniel Zepf · 2009 · Dialogues in Clinical Neuroscience
48. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial
    the EMC Study Group, André Tadić, Stanislav Gorbulev, Norbert Dahmen, Christoph Hiemke, Dieter F. Braus, Joachim Roschke, Dietrich van Calker, Daniel Wachtlin, Kai Kronfeld et al. · 2010 · Trials
49. Vilazodone in the treatment of major depressive disorder
    Arif Khan, Angelo Sambunaris, John G. Edwards, Adam Ruth, Donald S. Robinson · 2013 · International Clinical Psychopharmacology
50. Surrogate markers of treatment outcome in major depressive disorder
    George I. Papakostas · 2011 · The International Journal of Neuropsychopharmacology
51. Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients
    M. Vermeiden, A. Kamperman, Monique E. Vulink, W. W. van den Broek, T. Birkenhäger · 2014 · Psychopharmacology
52. Randomized, double‐blind, placebo‐controlled study of methylphenidate for the treatment of depression in SSRI‐treated cancer patients receiving palliative care
    Donald Richard Sullivan, Solange Mongoue‐Tchokote, Motomi Mori, Elizabeth Goy, Linda K. Ganzini · 2016 · Psycho-Oncology
53. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, phase 2 clinical trial
    Masaki Kato, Kazuyuki Nakagome, Takamichi Baba, Takuhiro Sonoyama, Daiki Okutsu, Hideki Yamanaka, Ryosuke Shimizu, Tomoko Motomiya, Takeshi Inoue · 2023 · Psychiatry and Clinical Neurosciences
54. Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis
    Linda Petronella Martina Maria Wijlaars, Irwin Nazareth, Heather Whitaker, Stephen J. W. Evans, Irene Petersen · 2013 · BMJ Open
55. LATENT CLASSES OF NONRESPONDERS, RAPID RESPONDERS, AND GRADUAL RESPONDERS IN DEPRESSED OUTPATIENTS RECEIVING ANTIDEPRESSANT MEDICATION AND PSYCHOTHERAPY
    Michel A. Thibodeau, Lena Catherine Quilty, Filip De Fruyt, Marleen De Bolle, F. Rouillon, Robert Michael Bagby · 2014 · Depression and Anxiety
56. Brief Web-Based Intervention for Depression: Randomized Controlled Trial on Behavioral Activation
    Lena Jelinek, Sönke Arlt, Steffen Moritz, Johanna Schröder, Stefan Westermann, Barbara Cludius · 2019 · Journal of Medical Internet Research
57. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    David S. Baldwin, Edward Ernest Schweizer, Yikang Xu, Gavin J. Lyndon · 2011 · European Neuropsychopharmacology
58. Can effects of antidepressants in patients with mild depression be considered as clinically significant?
    Ulrich Hegerl, Antje‐Kathrin Allgaier, Verena Henkel, Roland Mergl · 2011 · Journal of Affective Disorders
59. Early Improvement and Serum Concentrations of Citalopram to Predict Antidepressant Drug Response of Patients with Major Depression
    Elnaz Ostad Haji, A. Tadić, Stefanie Wagner, A. Dragivevic, M. Müller, Katja Boland, MG Rao, M Fric, Gerd Laux, Christoph Hiemke · 2013 · Pharmacopsychiatry
60. Sertraline effects on cerebrospinal fluid monoamines and species-typical socioemotional behavior of female cynomolgus monkeys
    Carol A. Shively, Thomas C. Register, James Dee Higley, Stephanie L. Willard · 2013 · Psychopharmacology
61. Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti‐depressive drug on the market
    Jules Baudot, Thomas Soeiro, Marine Tambon, Nicolas Navarro, Gwenaëlle Veyrac, Salim Mezaache, Joëlle Micallef · 2021 · Fundamental and Clinical Pharmacology
62. Systematic evaluation of a predator stress model of depression in mice using a hierarchical 3D-motion learning framework
    Yu-Ting Tseng, Binghao Zhao, Hui Ding, Lisha Liang, Bernhard Schaefke, Liping Wang · 2023 · Translational Psychiatry
63. Ketamine as a rapid antidepressant: the debate and implications
    Roger Ho, Melvyn W. Zhang · 2016 · BJPsych Advances
64. Serotonin Transporter Gene Polymorphism Associated with Short-Term Treatment Response to Venlafaxine
    Sang‐Hyuk Lee, Tae-Kyou Choi, Eun Min Lee, Jeong‐Ho Seok, Sung Hee Lee, Hong Shick Lee, Se Joo Kim · 2010 · Neuropsychobiology
65. Allelic variation in 5-HTTLPR and the effects of citalopram on the emotional neural network
    Ma, Yina, Li, Bingfeng, Wang, Chenbo, Zhang, Wenxia, Rao, Yi, Han, Shihui · 2015 · British Journal of Psychiatry
66. Prescribing selective serotonin reuptake inhibitors in older age.
    A. Topiwala, Leonidas Chouliaras, Klaus P. Ebmeier · 2014 · Maturitas
67. Bringing back melancholia
    Bernard J. Carroll · 2012 · Bipolar Disorders
68. The effects of six-day SSRI administration on diurnal cortisol secretion in healthy volunteers
    Amy Ronaldson, Livia Araujo de Carvalho, Karen Kostich, Antonio Ivan Lazzarino, Livia Urbanova, Andrew Steptoe · 2018 · Psychopharmacology
69. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial
    Ramin Hamidi Farahani, Ali Ajam, Alireza Ranjbar Naeini · 2023 · BMC Infectious Diseases
70. A multiscale inflammatory map: linking individual stress to societal dysfunction
    Yoram Vodovotz B, Julia C. Arciero, Paul F. M. J. Verschure, David L. Katz · 2024 · Frontiers in Science
71. History of suicide attempts among patients with depression in the GENDEP project
    Nader Ali Perroud, Rudolf Uher, Joanna Hauser, Marcella Rietschel, Neven Henigsberg, Anna Placentino, Dejan Kozel, Wolfgang Maier, Ole N Mors, Daniel Souery et al. · 2009 · Journal of Affective Disorders
72. Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
    Brian E. Leonard, David M. Taylor · 2010 · Journal of Psychopharmacology
73. Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis
    Chris F. A. Johnson, Margaret Maxwell, Brian Williams, Nadine J Dougall, Stephen A. MacGillivray · 2022 · BMJ Medicine
74. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis
    Zejun Li, Qiuxia Wu, Pu Peng, Min Wu, Shouhuan Liu, Tieqiao Liu · 2023 · Psychiatry Research
75. Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers
    MJ Taylor, Ray Norbury, Susannah Elinor Murphy, Sarah R. Rudebeck, Peter Jezzard, Philip J. Cowen · 2009 · Journal of Psychopharmacology
76. Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment
    Lara F. Alexander, Alison M. Oliver, Lauren K. Burdine, Yi‐lang Tang, Boadie Waid Dunlop · 2017 · Psychiatry Research
77. Acute and chronic effects of citalopram on 5‐HT1Areceptor—Labeling by [18F]MPPF and—Coupling to receptors‐G proteins
    Marcelle Moulin Sallanon, Yves Charnay, Nathalie Ginovart, Pascale Perret, Laurence Lanfumey, M. Hamon, René Hen, Daniel Fagret, Vicente Ibáñez, P. Millet · 2008 · Synapse
78. Dietary tryptophan depletion according to body weight – A new treatment option in acute mania?
    Florian Daniel Zepf, Lars Wöckel, Fritz Poustka, Martin H. Holtmann · 2008 · Medical Hypotheses
79. Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis
    James C. Ballenger · 2008 · Yearbook of Psychiatry and Applied Mental Health
80. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder—A psychometric approach
    D. Adkins, K. Åberg, J. McClay, J. Hettema, S. Kornstein, József Bukszár, E. van den Oord · 2010 · Biological Psychiatry
81. Symptom‐specific effects of cognitive‐behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders.
    Cervin, Matti, Storch, Eric A., Piacentini, John, Birmaher, Boris, Compton, Scott N., Albano, Anne Marie, Gosch, Elizabeth, Walkup, John T., Kendall, Philip C. · 2020 · Journal of Child Psychology and Psychiatry
82. Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder
    Ai-Xia Zhang, Xin Wang, Jianying Li, Lin Jing, Xiaodong Hu, Hejun Li, Chun-Xia Yang, Kerang Zhang, N. Sun · 2022 · Frontiers in Neuroscience
83. Are antidepressants useful in the treatment of minor depression
    Ulrich Hegerl, Peter Schönknecht, Roland Mergl · 2011 · Current Opinion in Psychiatry
84. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials
    Rakesh Jain, Dalei Chen, John Edwards, Maju Mathews · 2013 · Current Medical Research and Opinion
85. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial
    George Salaminios, Larisa Duffy, Anthony E. Ades, Ricardo Araya, Katherine Susan Button, Rachel C. Churchill, Tim J. Croudace, Catherine Derrick, Padraig Dixon, Christopher F Dowrick et al. · 2017 · Trials
86. Rapid onset of true antidepressant action
    Matthew John Taylor · 2007 · Current Psychiatry Reports
87. Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine
    Raymond Wing Moon Lam · 2010 · Journal of Psychopharmacology
88. Decreasing Preoperative Anxiety in Patients with Newly Available Multimodal Approaches—A Narrative Review
    Weronika Kisielewska, Michał Kościółek, Weronika Kowalczyk, Bernard Mitura, Lidia Mitura, Sylwester Rogula, Piotr Leszczyński, Katarzyna Antosik, Kryspin Mitura · 2025 · Journal of Clinical Medicine
89. Association of Medicaid Expansion With Postpartum Depression Treatment in Arkansas
    Maria W. Steenland, Amal N. Trivedi · 2023 · JAMA Health Forum
90. Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone
    Umberto Albert, Carmine Tomasetti, Camillo Marra, Francesca Neviani, Alessandro Pirani, Daiana Taddeo, Orazio Oz. Zanetti, Giuseppe Maina · 2023 · Frontiers in Psychiatry
91. Cortical Thickness Predicts Response Following 2 Weeks of SSRI Regimen in First-Episode, Drug-Naive Major Depressive Disorder: An MRI Study
    Peiyi Wu, Ai‐Xia Zhang, Ning Sun, Lei Lei, Penghong Liu, Yikun Wang, Hejun Li, Chunxia Yang, Kerang Zhang · 2022 · Frontiers in Psychiatry
92. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data
    M. Bareš, T. Novák, M. Kopeček, P. Stopková, Jiri Kozeny, C. Höschl · 2012 · European psychiatry
93. Peripheral Biomarkers in Animal Models of Major Depressive Disorder
    Lucia Carboni · 2013 · Disease Markers
94. Suggestibility as a predictor of response to antidepressants: A preliminary prospective trial
    Uri Nitzan, Yossi Chalamish, Israel Krieger, Hany Burstein Erez, Yoram Braw, Pesach Lichtenberg · 2015 · Journal of Affective Disorders
95. Biomarkers for Deep Brain Stimulation in Animal Models of Depression
    Jason Yuen, Aaron E. Rusheen, J. Blair Price, Abhijeet S. Barath, Hojin Shin, Abbas Z. Kouzani, Michael Berk, Charles D. Blaha, Kendall H. Lee, Yoonbae Oh · 2021 · Neuromodulation Technology at the Neural Interface
96. The darkness and the light: diurnal rodent models for seasonal affective disorder
    Anusha Shankar, Cory T. Williams · 2021 · Disease Models & Mechanisms
97. Subdiagnostische Depressionen
    Ulrich Hegerl, Peter Schönknecht · 2009 · Der Nervenarzt
98. SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC?
    Philip J. Cowen · 2023 · Current topics in behavioral neurosciences
99. Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
    A. Becker, Mélusine Humbert‐Droz, Lorenz Mueller, Alen Jelušić, Avram Tolev, Isabelle Straumann, Isidora Avedisian, Livio Erne, Jan Thomann, Dino Luethi et al. · 2025 · Clinical Pharmacology & Therapeutics
100. Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome level
     Magdalena Kolasa, Maciej Kuśmider, Joanna Solich, Agata Faron‐Górecka, Małgorzata J. Krawczyk, KRZYSZTOF KUŁAKOWSKI, Marta Dziedzicka‐Wasylewska · 2012 · Psychopharmacology